Business Context and Reporting Period
Company: Pro-Pharmaceuticals, Inc. (Note: Input metadata listed "Galectin Therapeutics," but the filing text identifies the registrant as Pro-Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: A development-stage biotechnology company focused on discovering and developing carbohydrate-based therapeutics, primarily to enhance existing cancer treatments. The lead product candidate is DAVANAT®, a patented polysaccharide intended to increase the efficacy and reduce the toxicity of chemotherapy drugs like 5-FU when used in combination. The company has no commercial products and has not generated any revenue to date.
Key Financial Metrics
| Metric | 2008 | 2007 | Cumulative (Inception to 2008) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(3.15) million | $(9.43) million | $(38.31) million |
| Net Loss Applicable to Common Stock | $(3.39) million | $(9.43) million | $(38.55) million |
| Research & Development Expenses | $(1.77) million | $(2.05) million | $(17.36) million |
| General & Administrative Expenses | $(3.55) million | $(4.40) million | $(26.01) million |
| Cash and Cash Equivalents (Year End) | $0.32 million | $1.32 million | N/A |
| Total Assets | $0.70 million | $1.78 million | N/A |
| Total Liabilities | $1.17 million | $4.71 million | N/A |
| Stockholders' Deficit | $(0.47) million | $(2.92) million | N/A |
| Accumulated Deficit | $(38.55) million | $(35.16) million | $(38.55) million |
Liquidity: As of December 31, 2008, the company held approximately $318,000 in unrestricted cash. Following a financing event on February 12, 2009, cash on hand was approximately $900,000 as of March 20, 2009. Management estimates this is sufficient to fund operations only until June 2009.
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss decreased significantly from $9.43 million in 2007 to $3.15 million in 2008. This improvement was primarily driven by a $5.15 million swing in "Other Income and Expense," largely due to a $2.15 million gain from the change in fair value of warrant liabilities and the repayment of convertible debt in 2007 which eliminated related interest expenses.
- Operating Expenses: Total operating expenses decreased by approximately $1.13 million. Research and Development (R&D) expenses fell by $279,000 due to reduced activity in Phase II clinical trials as the company focused on regulatory filings. General and Administrative (G&A) expenses decreased by $850,000, attributed to lower legal/accounting fees and salary reductions.
- Stock Delisting: The company's common stock was delisted from the NYSE Alternext US on January 9, 2009, and began trading on the OTC Bulletin Board.
- Leadership Changes: On February 12, 2009, the former CEO and Chairman, David Platt, Ph.D., resigned. Theodore Zucconi, Ph.D., was named the new CEO and President.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
The company has no formal financial guidance. Management states it must raise additional capital by June 2009 to continue operations. Failure to do so may result in significantly curtailed operations, cessation of operations, or seeking federal bankruptcy protection. The company is pursuing a 505(b)(2) New Drug Application (NDA) for DAVANAT® in combination with 5-FU for colorectal cancer, though the FDA has indicated a Phase III trial is required to demonstrate superiority to the standard of care.
Going Concern Warning
The auditors have issued a "going concern" opinion. The company has incurred recurring losses, has a stockholders' deficit, and has raised substantial doubt about its ability to continue as a going concern without additional financing.
Key Risks and Contingencies
- Capital Requirements: Immediate need for funding by June 2009. The company entered a securities purchase agreement in February 2009 for up to $6.0 million in preferred stock and warrants, with an initial closing of $1.5 million.
- Intellectual Property Litigation: The company is a counterclaim defendant in a lawsuit filed by Prospect Therapeutics, Inc. (formerly GlycoGenesys) regarding intellectual property rights. A trial commenced in March 2009. An adverse outcome could prevent the exclusive use of the company's core technology.
- Contract Dispute: The company is involved in litigation with Summer Street Research Partners regarding placement fees. The company believes the claim is without merit.
- Regulatory Uncertainty: Success depends on FDA approval, which is uncertain. The FDA has requested a Phase III trial for the lead product, which is costly and time-consuming.
Investor Verification Checklist
- Cash Runway: Verify the status of the Series B Preferred Stock financing and whether subsequent closings have occurred to extend the cash runway beyond June 2009.
- Legal Proceedings: Monitor the outcome of the intellectual property lawsuit with Prospect Therapeutics, Inc., as a loss could invalidate the company's core patent portfolio.
- FDA Status: Confirm the current status of the DAVANAT® NDA submission and the specific requirements for the requested Phase III trial.
- Stock Liquidity: Assess the trading volume and liquidity of the stock on the OTC Bulletin Board following the delisting from NYSE Alternext US.
- Executive Compensation: Review the terms of the Separation Agreement with the former CEO, David Platt, which includes deferred salary and a potential $1.0 million severance payment contingent on specific milestones.